Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + cisplatin + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Cetuximab + cisplatin + pemetrexed is a combination therapy that has been investigated in clinical trials for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma. This regimen combines a monoclonal antibody targeting EGFR (cetuximab) with a platinum-based chemotherapy agent (cisplatin) and an antifolate antineoplastic agent (pemetrexed).
- Other names
- pemetrexed + cisplatin + cetuximab
02
Targets
DHFR (Dihydrofolate reductase)DNAEGFR (Epidermal growth factor receptor)TS (Thymidylate synthase)GART (GAR transformylase)
Beyond the preview
Go deeper on cetuximab + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + cisplatin + pemetrexed.